WSJ: Drugmaker CEOs aren't buying Silicon Valley's promise that AI will cure disease
zzzeek · hn · 2026-11-09
A WSJ report finds that while Silicon Valley keeps promising AI will revolutionize drug discovery and cure disease, CEOs of major pharmaceutical companies remain skeptical. They see a gap between AI hype and its actual contribution to real R&D pipelines, while AI startups continue to pitch disruptive narratives to investors. HN discussion debates the practical limits of AI in biomedicine.
More from Companies & People
- Humanoid robotics lab recruiting PhD students and postdocs at CoRL: wild loco-manipulation, dexterity — GhaffariMaani · 2026-11-09
- Nvidia CEO Jensen Huang admits affair, board to launch investigation — Scobleizer · 2026-11-09
- McKinsey: Top 20-25% of Companies See 2x AI Coding Gains — Here's What They Do Differently — AI Engineer · 2026-11-09
- Accenture research paper found to contain 15 AI-hallucinated citations — jonerp · 2026-11-09
- Apple Pressured to Accelerate Agentic Siri With Fine-Grained First-Party App Control — The Verge AI · 2026-11-09
- Speaker claims Anthropic 'jacked her swag' with agent memory post — michellechen · 2026-11-09